Literature DB >> 19720366

Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States.

G Thomas Ray1, Stephen I Pelton, Keith P Klugman, David R Strutton, Matthew R Moore.   

Abstract

Seven-valent pneumococcal conjugate vaccine (PCV7) has been in routine use in the United States since 2000 and data have indicated direct and indirect effects of the vaccine. We simulated the effects of PCV7 on children vaccinated during 2000-2006, incorporating direct and indirect effects on incidence of invasive pneumococcal disease (IPD), hospitalized pneumonia and otitis media. Before accounting for indirect effects, PCV7 cost $201,000 per life-year saved. After incorporating indirect effects on IPD, cost per life-year saved was $10,400. The presence of modest additional indirect effects against hospitalized pneumonia and otitis media in children may have resulted in overall cost savings.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19720366     DOI： 10.1016/j.vaccine.2009.08.045

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  18 in total

1.  Genome-wide identification of Streptococcus pneumoniae genes essential for bacterial replication during experimental meningitis.

Authors:  T E Molzen; P Burghout; H J Bootsma; C T Brandt; Christa E van der Gaast-de Jongh; M J Eleveld; M M Verbeek; N Frimodt-Møller; C Østergaard; P W M Hermans
Journal:  Infect Immun       Date:  2010-11-01       Impact factor: 3.441

2.  Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany.

Authors:  Alexander Kuhlmann; J-Matthias Graf von der Schulenburg
Journal:  Eur J Health Econ       Date:  2016-02-23

Review 3.  Cost effectiveness of pneumococcal conjugate vaccination against acute otitis media in children: a review.

Authors:  Chantal W B Boonacker; Pieter H Broos; Elisabeth A M Sanders; Anne G M Schilder; Maroeska M Rovers
Journal:  Pharmacoeconomics       Date:  2011-03       Impact factor: 4.981

4.  Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.

Authors:  Michael R Jacobs; Caryn E Good; Anne R Windau; Saralee Bajaksouzian; Donald Biek; Ian A Critchley; Helio S Sader; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

5.  An economic model assessing the value of microneedle patch delivery of the seasonal influenza vaccine.

Authors:  Bruce Y Lee; Sarah M Bartsch; Mercy Mvundura; Courtney Jarrahian; Kristina M Zapf; Kathleen Marinan; Angela R Wateska; Bill Snyder; Savitha Swaminathan; Erica Jacoby; James J Norman; Mark R Prausnitz; Darin Zehrung
Journal:  Vaccine       Date:  2015-03-13       Impact factor: 3.641

6.  Potential impact of introducing the pneumococcal conjugate vaccine into national immunisation programmes: an economic-epidemiological analysis using data from India.

Authors:  Itamar Megiddo; Eili Klein; Ramanan Laxminarayan
Journal:  BMJ Glob Health       Date:  2018-05-09

7.  Emergence of Streptococcus pneumoniae serogroups 15 and 35 in nasopharyngeal cultures from young children with acute otitis media.

Authors:  Judith M Martin; Alejandro Hoberman; Jack L Paradise; Karen A Barbadora; Nader Shaikh; Sonika Bhatnagar; Timothy Shope; Stan L Block; Mary Ann Haralam; Marcia Kurs-Lasky; D Kathleen Colborn; Michael Green
Journal:  Pediatr Infect Dis J       Date:  2014-11       Impact factor: 2.129

Review 8.  Twenty-Year Public Health Impact of 7- and 13-Valent Pneumococcal Conjugate Vaccines in US Children.

Authors:  Matt Wasserman; Ruth Chapman; Rotem Lapidot; Kelly Sutton; Desmond Dillon-Murphy; Shreeya Patel; Erica Chilson; Vincenza Snow; Raymond Farkouh; Stephen Pelton
Journal:  Emerg Infect Dis       Date:  2021       Impact factor: 6.883

9.  Carriage of Streptococcus pneumoniae 3 years after start of vaccination program, the Netherlands.

Authors:  Judith Spijkerman; Elske J M van Gils; Reinier H Veenhoven; Eelko Hak; Ed P F Yzerman; Arie van der Ende; Alienke J Wijmenga-Monsuur; Germie P J M van den Dobbelsteen; Elisabeth A M Sanders
Journal:  Emerg Infect Dis       Date:  2011-04       Impact factor: 6.883

10.  Impact of 13-valent pneumococcal conjugate vaccine (PCV13) in a pandemic similar to the 2009 H1N1 in the United States.

Authors:  Lisa J McGarry; Kristen E Gilmore; Jaime L Rubin; Keith P Klugman; David R Strutton; Milton C Weinstein
Journal:  BMC Infect Dis       Date:  2013-05-21       Impact factor: 3.090
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.